This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / NeOnc NEO212 Abu Dhabi IND
Regulatory regulatory approval

NeOnc NEO212 Abu Dhabi IND

Analysis based on 6 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The IND authorization for NEO212 in Abu Dhabi provides Neonci Technologies with an additional clinical development pathway, potentially accelerating its drug development and market reach. This positive regulatory news, coupled with promising clinical data for NEO100 and significant insider buying, is likely to boost investor confidence in Neonci Technologies, potentially leading to an increase in its stock price and attracting further institutional interest.

biotechnology pharmaceuticals
Event Summary

Neonci Technologies, a neuro-oncology company, received Investigational New Drug (IND) authorization from the United Arab Emirates — Department of Health – Abu Dhabi for its drug NEO212, an oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This is the first international regulatory clearance for NEO212, establishing a clinical development pathway outside the United States. The company is also advancing NEO100, a patented intranasal composition, which has shown tumor remission in approximately 24% of recurrent glioblastoma patients in its Phase 2a study. CEO Amir Heshmatpour has also been actively buying company stock, demonstrating confidence in Neonci Technologies's future. These developments are seen as significant catalysts for the company.

Entities Involved
priv
Neonci Technologies
Neonci Technologies received IND authorization for NEO212 from the United Arab Emirates — Department of Health – Abu Dhabi, marking its first international regulatory clearance. This approval creates an additional clinical development pathway outside the United States and is a significant milestone for the company's neuro-oncology programs.
Importance 100.0 Sentiment 70.0
govactor
United Arab Emirates — Department of Health – Abu Dhabi
The United Arab Emirates — Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, a key regulatory approval for Neonci Technologies.
Importance 80.0 Sentiment 0.0
per
Amir Heshmatpour
Amir Heshmatpour, Chairman, President, and CEO of Neonci Technologies, has been actively buying company stock, indicating confidence in the company's long-term strategy and development prospects.
Importance 70.0 Sentiment 50.0
stock
State Street Corporation
State Street Corporation is one of the major financial institutions through which Wall Street awareness of Neonci Technologies has expanded.
Importance 10.0 Sentiment 0.0
stock
Bank of America
Bank of America is one of the major financial institutions through which Wall Street awareness of Neonci Technologies has expanded.
Importance 10.0 Sentiment 0.0
stock
Barclays
Barclays is one of the major financial institutions through which Wall Street awareness of Neonci Technologies has expanded.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
Bank of America related ↔ Barclays
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.